Evidence map›Paper›PMID 28500376›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2017

The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.

Daniela Josabeth López-Cano, Daniel Cadena-Sandoval, Olga Beltrán-Ramírez, Rosa Elda Barbosa-Cobos, Fausto Sánchez-Muñoz, Luis Manuel Amezcua-Guerra, Yaneli Juárez-Vicuña, María Concepción Aguilera-Cartas, José Moreno, Jesús Bautista-Olvera and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Analysis ofDiagnostics (Basel, Switzerland) · 2023
    Article
  6. Review
  7. BLK and BANK1 polymorphisms and interactions are associated in Mexican patients with systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Article
  8. An association study in PTPN22 suggests that is a risk factor to Takayasu's arteritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Functional polymorphisms inOncotarget · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Daniela Josabeth López-CanoResearch Unit on Endocrine and Metabolic Diseases, Hospital Juárez de México (HJM), Av. Instituto Politécnico Nacional No. 5160, Delegación Gustavo A. Madero, 07760, Mexico City, D.F., Mexico.
Daniel Cadena-SandovalResearch Unit on Endocrine and Metabolic Diseases, Hospital Juárez de México (HJM), Av. Instituto Politécnico Nacional No. 5160, Delegación Gustavo A. Madero, 07760, Mexico City, D.F., Mexico.
Olga Beltrán-RamírezResearch Unit on Immunity and Inflammation, HJM, Mexico City, Mexico.
Rosa Elda Barbosa-CobosDepartment of Rheumatology, HJM, Mexico City, Mexico.
Fausto Sánchez-MuñozDepartment of Immunology, National Institute of Cardiology (NIC), Mexico City, Mexico.
Luis Manuel Amezcua-GuerraDepartment of Immunology, National Institute of Cardiology (NIC), Mexico City, Mexico.
Yaneli Juárez-VicuñaDepartment of Immunology, National Institute of Cardiology (NIC), Mexico City, Mexico.
María Concepción Aguilera-CartasDepartment of Endocrinology, HJM, Mexico City, Mexico.
José MorenoDirection of Research, HJM, Mexico City, Mexico.
Jesús Bautista-OlveraBlood Bank, HJM, Mexico City, Mexico.
Guillermo Valencia-PachecoLaboratory of Hematology, Regional Research Center, Autonomous University of Yucatan, Mérida, Yucatan, Mexico.
Ricardo F López-VillanuevaRegional General Hospital (ISSSTE), Health Services Yucatan (HSY), Mérida, Yucatan, Mexico.
Julian Ramírez-BelloResearch Unit on Endocrine and Metabolic Diseases, Hospital Juárez de México (HJM), Av. Instituto Politécnico Nacional No. 5160, Delegación Gustavo A. Madero, 07760, Mexico City, D.F., Mexico. dr.julian.ramirez.hjm@gmail.com.ORCID http://orcid.org/0000-0002-4153-9315
Instituto Nacional de Cardiología · MXHospital Juárez de México · MXAutonomous University of Yucatán · MXInstitute for Social Security and Services for State Workers · MXTecnológico Nacional de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe functional PTPN22 R620W polymorphism (rs2476601) is clearly associated with susceptibility to several autoimmune diseases (ADs). However, the PTPN22 R263Q polymorphism (rs33996649) has been scarcely explored in different ADs. Here we aimed to examine the associations of the PTPN22 R620W and R263Q polymorphisms with susceptibility to or protection against rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Graves' disease (GD) among Mexican patients.

methodsWe conducted a case-control study including 876 patients (405 with SLE, 388 with RA, and 83 with GD) and 336 healthy control individuals. PTPN22 genotypes were determined using the TaqMan 5' allele discrimination assay.

resultsPTPN22 R620W was associated with GD susceptibility (OR 4.3, p = 0.004), but was not associated with SLE (OR 1.8, p = 0.19). We previously demonstrated that this polymorphism is associated with RA susceptibility (OR 4.17, p = 0.00036). Moreover, PTPN22 R263Q was associated with protection against SLE (OR 0.09, p = 004) and RA (OR 0.28, p = 0.045), but was not associated with GD.

conclusionsOur data provide the first demonstration that PTPN22 R620W confers GD susceptibility among Latin-American patients. Moreover, this is the second report documenting the association of PTPN22 R263Q with protection against SLE and RA.

Indexed as

AdultArthritis, RheumatoidCase-Control StudiesFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeGraves DiseaseHispanic or LatinoHumansLupus Erythematosus, SystemicMaleMexicoMiddle AgedPolymorphism, Single NucleotideProtein Tyrosine Phosphatase, Non-Receptor Type 22Protein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, humanGraves’ diseasePTPN22Rheumatoid arthritisSystemic lupus erythematosus

Identifiers

PMID28500376
OpenAlexW2612318692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.